Clinical trialsCompany release

Climb Bio's CLYM116 data support 12-week dosing as budoprutug programmes advance

🇺🇸 Climb Bio, Inc. (CLYM) · Thu 05 Nov 2026

Climb Bio's Q3 2026 update reports sustained APRIL suppression at 12 weeks for CLYM116, a Phase 2 IgA nephropathy start, and cash expected to last into H2 2028.

Climb Bio reported its third-quarter 2026 results on 5 November 2026, alongside updates on its two lead antibody programmes. The source text of the release was not available, so this report relies on the company's summary of the announcement.

Phase 1 data in healthy volunteers for CLYM116, an anti-APRIL antibody, showed free APRIL suppression was sustained at 12 weeks. Climb Bio says this supports dosing every 12 weeks. Dosing has begun in NAVIGATE-2, a Phase 2 trial in IgA nephropathy.

Budoprutug, an anti-CD19 antibody, showed B-cell depletion and a favourable safety profile in studies in primary membranous nephropathy and lupus. Further data in immune thrombocytopenia (ITP) are due at the American Society of Hematology (ASH) meeting in December.

Climb Bio reported cash of $227.6 million, which it expects to fund operations into the second half of 2028. The summary gives no further financial detail.

What it means for your team

  • A 12-week dosing interval for CLYM116, if confirmed in patients, would be a key factor in its tolerability and convenience profile; the current data come only from healthy volunteers.
  • Budoprutug is being studied across several autoimmune indications, so safety data from each population will matter for future regulatory discussions.
  • Watch the ASH presentation in December for additional ITP data on budoprutug.
  • The stated cash runway into the second half of 2028 indicates the company's expected timeline for its current trials.

Company's press release (SEC filing): Climb Bio, Inc. ↗

Article written by VigiEye from the official source (Climb Bio, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →